204 related articles for article (PubMed ID: 28930612)
1. Genetic addiction risk score (GARS) ™, a predictor of vulnerability to opioid dependence.
Blum K; Chen ALC; Thanos PK; Febo M; Demetrovics Z; Dushaj K; Kovoor A; Baron D; Smith DE; Roy AK; Fried L; Chen TJH; Chapman E; Modestino EJ; Steinberg B; Badgaiyan RD
Front Biosci (Elite Ed); 2018 Jan; 10(1):175-196. PubMed ID: 28930612
[TBL] [Abstract][Full Text] [Related]
2. High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial.
Moran M; Blum K; Ponce JV; Lott L; Gondré-Lewis MC; Badgaiyan S; Brewer R; Downs BW; Fynman P; Weingarten A; Cadet JL; Smith DE; Baron D; Thanos PK; Modestino EJ; Badgaiyan RD; Elman I; Gold MS
Mol Neurobiol; 2021 Jul; 58(7):3335-3346. PubMed ID: 33683627
[TBL] [Abstract][Full Text] [Related]
3. The Benefits of Genetic Addiction Risk Score (GARS
Blum K; Modestino EJ; Gondre-Lewis M; Chapman EJ; Neary J; Siwicki D; Baron D; Hauser M; Smith DE; Roy AK; Thanos PK; Steinberg B; McLaughlin T; Fried L; Barh D; Dunston GA; Badgaiyan RD
Int J Genom Data Min; 2018; 2018(1):. PubMed ID: 30198022
[TBL] [Abstract][Full Text] [Related]
4. Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility.
Blum K; Hauser M; Fratantonio J; Badgaiyan RD
Addict Genet; 2015 Jul; 2(1):1-5. PubMed ID: 26807291
[TBL] [Abstract][Full Text] [Related]
5. Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors.
Gupta A; Bowirrat A; Gomez LL; Baron D; Elman I; Giordano J; Jalali R; Badgaiyan RD; Modestino EJ; Gold MS; Braverman ER; Bajaj A; Blum K
Int J Environ Res Public Health; 2022 Jan; 19(1):. PubMed ID: 35010811
[TBL] [Abstract][Full Text] [Related]
6. Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions.
Chen AL; Chen TJ; Waite RL; Reinking J; Tung HL; Rhoades P; Downs BW; Braverman E; Braverman D; Kerner M; Blum SH; DiNubile N; Smith D; Oscar-Berman M; Prihoda TJ; Floyd JB; O'Brien D; Liu HH; Blum K
Med Hypotheses; 2009 Jan; 72(1):14-22. PubMed ID: 18951726
[TBL] [Abstract][Full Text] [Related]
7. Molecular neurological correlates of endorphinergic/dopaminergic mechanisms in reward circuitry linked to endorphinergic deficiency syndrome (EDS).
Blum K; Baron D; McLaughlin T; Gold MS
J Neurol Sci; 2020 Apr; 411():116733. PubMed ID: 32088516
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomics and prescription opioid use.
Benjeddou M; Peiró AM
Pharmacogenomics; 2021 Mar; 22(4):235-245. PubMed ID: 33445954
[TBL] [Abstract][Full Text] [Related]
9. Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction.
Blum K; Badgaiyan RD; Agan G; Fratantonio J; Simpatico T; Febo M; Haberstick BC; Smolen A; Gold MS
J Reward Defic Syndr; 2015; 1(1):65-68. PubMed ID: 26052557
[TBL] [Abstract][Full Text] [Related]
10. Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine.
Abijo T; Blum K; Gondré-Lewis MC
Curr Neuropharmacol; 2020; 18(7):578-595. PubMed ID: 31744450
[TBL] [Abstract][Full Text] [Related]
11. Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?
Gold MS; Baron D; Bowirrat A; Blum K
J Neurol Sci; 2020 Nov; 418():117137. PubMed ID: 32957037
[TBL] [Abstract][Full Text] [Related]
12. Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated).
Kenneth B; Edward MJ; Marjorie GLC; David B; Bruce S; Panayotis TK; William DB; Davis S; Lisa L; Eric BR; Mark M; David M; Lyle F; Rajendra BD
CPQ Neurol Psychol; 2018; 1(2):. PubMed ID: 30957097
[TBL] [Abstract][Full Text] [Related]
13. Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.
Kreek MJ; Levran O; Reed B; Schlussman SD; Zhou Y; Butelman ER
J Clin Invest; 2012 Oct; 122(10):3387-93. PubMed ID: 23023708
[TBL] [Abstract][Full Text] [Related]
14. Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).
Blum K; Oscar-Berman M; Demetrovics Z; Barh D; Gold MS
Mol Neurobiol; 2014 Dec; 50(3):765-96. PubMed ID: 24878765
[TBL] [Abstract][Full Text] [Related]
15. A potential paradigm shift in opioid crisis management: The role of pharmacogenomics.
Eapen-John D; Mohiuddin AG; Kennedy JL
World J Biol Psychiatry; 2022 Jul; 23(6):411-423. PubMed ID: 34854362
[TBL] [Abstract][Full Text] [Related]
16. Opioid neuropeptide genotypes in relation to heroin abuse: dopamine tone contributes to reversed mesolimbic proenkephalin expression.
Nikoshkov A; Drakenberg K; Wang X; Horvath MC; Keller E; Hurd YL
Proc Natl Acad Sci U S A; 2008 Jan; 105(2):786-91. PubMed ID: 18184800
[TBL] [Abstract][Full Text] [Related]
17. Relative addictive potential of opioid analgesic agents.
Connors NJ; Mazer-Amirshahi M; Motov S; Kim HK
Pain Manag; 2021 Mar; 11(2):201-215. PubMed ID: 33300384
[TBL] [Abstract][Full Text] [Related]
18. Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).
Blum K; Bowirrat A; Baron D; Lott L; Ponce JV; Brewer R; Siwicki D; Boyett B; Gondre-Lewis MC; Smith DE; Panayotis K T; Badgaiyan S; Hauser M; Fried L; A R; Downs BW; Badgaiyan RD
J Syst Integr Neurosci; 2020 Aug; 6(2):. PubMed ID: 33614164
[TBL] [Abstract][Full Text] [Related]
19. Promoting Precision Addiction Management (PAM) to Combat the Global Opioid Crisis.
Blum K; Modestino EJ; Neary J; Gondré-Lewis MC; Siwicki D; Moran M; Hauser M; Braverman ER; Baron D; Steinberg B; Laughlin TM; Badgaiyan RD
Biomed J Sci Tech Res; 2018 Jan; 2(2):1-4. PubMed ID: 30370423
[TBL] [Abstract][Full Text] [Related]
20. A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration.
Blum K; Kazmi S; Modestino EJ; Downs BW; Bagchi D; Baron D; McLaughlin T; Green R; Jalali R; Thanos PK; Elman I; Badgaiyan RD; Bowirrat A; Gold MS
J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33809702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
